Alaunos Therapeutics (TCRT) Competitors $1.77 -0.12 (-6.35%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.70 -0.08 (-4.24%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. CLDI, BLRX, NRSN, MTVA, EDSA, ATHA, XFOR, ABP, PRPH, and CYCCShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Calidi Biotherapeutics (CLDI), BioLineRx (BLRX), NeuroSense Therapeutics (NRSN), MetaVia (MTVA), Edesa Biotech (EDSA), Athira Pharma (ATHA), X4 Pharmaceuticals (XFOR), Abpro (ABP), ProPhase Labs (PRPH), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Its Competitors Calidi Biotherapeutics BioLineRx NeuroSense Therapeutics MetaVia Edesa Biotech Athira Pharma X4 Pharmaceuticals Abpro ProPhase Labs Cyclacel Pharmaceuticals Alaunos Therapeutics (NASDAQ:TCRT) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation. Which has stronger valuation & earnings, TCRT or CLDI? Alaunos Therapeutics has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlaunos Therapeutics$6K647.53-$4.68M-$2.46-0.72Calidi BiotherapeuticsN/AN/A-$29.22MN/AN/A Does the media prefer TCRT or CLDI? In the previous week, Calidi Biotherapeutics had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 5 mentions for Calidi Biotherapeutics and 3 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.39 beat Calidi Biotherapeutics' score of 0.13 indicating that Alaunos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alaunos Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Calidi Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, TCRT or CLDI? Alaunos Therapeutics has a beta of -0.81, indicating that its stock price is 181% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Do insiders & institutionals hold more shares of TCRT or CLDI? 27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is TCRT or CLDI more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alaunos TherapeuticsN/A -168.02% -121.37% Calidi Biotherapeutics N/A N/A -344.45% SummaryAlaunos Therapeutics beats Calidi Biotherapeutics on 6 of the 9 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.89M$2.54B$5.75B$9.62BDividend YieldN/A1.57%4.40%4.10%P/E Ratio-0.7222.9131.3026.05Price / Sales647.53554.08432.98193.75Price / CashN/A180.4637.7358.48Price / Book1.065.939.536.61Net Income-$4.68M$31.83M$3.26B$265.65M7 Day Performance-21.33%1.89%2.13%2.02%1 Month Performance-42.90%1.33%2.80%-0.31%1 Year Performance-37.68%8.84%30.68%19.06% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics1.1066 of 5 stars$1.77-6.3%N/A-35.2%$3.89M$6K-0.7240News CoverageHigh Trading VolumeCLDICalidi Biotherapeutics0.7413 of 5 stars$5.29+5.0%N/A-89.9%$16.01MN/A0.0038News CoverageBLRXBioLineRx3.411 of 5 stars$3.75+0.8%$26.00+593.3%-87.0%$15.98M$28.94M-0.4340NRSNNeuroSense Therapeutics2.5425 of 5 stars$1.12-6.7%$14.00+1,150.0%+41.8%$15.31MN/A-2.0710News CoveragePositive NewsShort Interest ↑Gap DownHigh Trading VolumeMTVAMetaVia2.0979 of 5 stars$0.63-1.1%$7.50+1,087.6%N/A$15.28MN/A0.008EDSAEdesa Biotech1.5461 of 5 stars$2.17+2.8%$5.00+130.4%-46.1%$15.26MN/A-1.6420ATHAAthira Pharma3.7946 of 5 stars$0.38+1.3%$11.25+2,823.6%-87.2%$15.18MN/A-0.2540News CoveragePositive NewsXFORX4 Pharmaceuticals4.1752 of 5 stars$2.58+81.3%$72.33+2,709.1%-82.8%$14.91M$2.56M-0.1780Analyst RevisionHigh Trading VolumeABPAbproN/A$0.25-1.1%$4.00+1,532.7%N/A$14.89M$180K0.0015PRPHProPhase Labs1.2369 of 5 stars$0.35+25.7%N/A-88.2%$14.71M$6.77M-0.28130High Trading VolumeCYCCCyclacel Pharmaceuticals0.4996 of 5 stars$9.28+2.5%N/A-97.2%$14.66M$40K-0.0114 Related Companies and Tools Related Companies Calidi Biotherapeutics Alternatives BioLineRx Alternatives NeuroSense Therapeutics Alternatives MetaVia Alternatives Edesa Biotech Alternatives Athira Pharma Alternatives X4 Pharmaceuticals Alternatives Abpro Alternatives ProPhase Labs Alternatives Cyclacel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access